[HTML][HTML] Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study
… to be related to use of evolocumab. However, other top reported reasons for evolocumab
therapy discontinuation, including reimbursement, patient request, and administrative decision, …
therapy discontinuation, including reimbursement, patient request, and administrative decision, …
[HTML][HTML] Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study
Introduction This study characterizes patients receiving evolocumab in clinical practice and
assesses treatment effectiveness, safety and persistence outcomes across five countries. …
assesses treatment effectiveness, safety and persistence outcomes across five countries. …
Evolocumab: a review in hyperlipidemia
GM Keating - American Journal of Cardiovascular Drugs, 2016 - Springer
… evolocumab was maintained in the longer term, and it was well tolerated. In conclusion,
subcutaneous evolocumab is a valuable new treatment for use … , particularly in patients unable to …
subcutaneous evolocumab is a valuable new treatment for use … , particularly in patients unable to …
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
… have demonstrated lipid-lowering efficacy across a broad patient population. In this
section, we highlight the effects of evolocumab in patients with and without familial …
section, we highlight the effects of evolocumab in patients with and without familial …
Evolocumab: considerations for the management of hyperlipidemia
BS Wiggins, J Senfield, H Kassahun, A Lira… - Current Atherosclerosis …, 2018 - Springer
… evolocumab in a pre-specified analysis of patients by LDL receptor mutation status. In patients
… in both alleles (of which at least one was defective), evolocumab reduced LDL-C by 41%. …
… in both alleles (of which at least one was defective), evolocumab reduced LDL-C by 41%. …
The efficacy of evolocumab in the management of hyperlipidemia: a systematic review
L AlHajri, A AlHadhrami, S AlMheiri… - Therapeutic …, 2017 - journals.sagepub.com
… the effectiveness of evolocumab in the management of hyperlipidemia. Evolocumab seems
to … Hence, it provides an excellent alternative for patients with refractory disease or patients …
to … Hence, it provides an excellent alternative for patients with refractory disease or patients …
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
… disease risks, and baseline use of lipid-lowering therapy. A … 1104 patients from the phase
2 trials compared evolocumab … evolocumab with placebo in patients with hyperlipidemia who …
2 trials compared evolocumab … evolocumab with placebo in patients with hyperlipidemia who …
[PDF][PDF] Evolocumab in hyperlipidemia
RJ Meyer - N Engl J Med, 2014 - researchgate.net
… (May 8 issue)2 on the durable effects of evolocumab in … were reported in four patients receiving
evolocumab (including two … occurred during treatment with evolocumab (no strokes were …
evolocumab (including two … occurred during treatment with evolocumab (no strokes were …
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
… of 12 Phase II or III evolocumab trials were eligible to … patients were randomized 2:1 to
receive evolocumab plus standard therapy or standard therapy alone. At week 12, evolocumab …
receive evolocumab plus standard therapy or standard therapy alone. At week 12, evolocumab …
[HTML][HTML] Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
… This analysis evaluated the effects of evolocumab in participants with mixed hyperlipidemia
(hypercholesterolemia with triglycerides ≥1.7 mmol/L [150 mg/dL]) and participants with …
(hypercholesterolemia with triglycerides ≥1.7 mmol/L [150 mg/dL]) and participants with …
相关搜索
- evolocumab use zerbini study
- mixed hyperlipidemia evolocumab in patients
- long term evolocumab in patients
- evolocumab in hyperlipidemia 52 week
- patients with hypercholesterolemia safety of evolocumab
- patients with hypercholesterolemia effect of evolocumab
- evolocumab use real world insights
- evolocumab use hyperlipidemia in saudi arabia
- evolocumab in the management patient selection
- evolocumab use canadian analysis
- evolocumab use clinical practitioners
- evolocumab use five countries
- pcsk9 inhibitor evolocumab in patients
- efficacy and safety evolocumab in patients
- patients with hyperlipidemia zerbini study